Zymeworks Analyst Ratings
Zymeworks Analyst Ratings
Stifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)
Zymeworks Analyst Ratings
Zymeworks Analyst Ratings
Buy Rating Affirmed for Zymeworks on Strong Pipeline and Upcoming Catalysts
Maintaining Hold on Zymeworks: ZW191's Potential Amidst Competitive and Regulatory Hurdles
Analysts' Top Healthcare Picks: Zymeworks (ZYME), 89bio (ETNB)
Zymeworks Analyst Ratings
Buy Rating Affirmed for Zymeworks Amid Positive HERIZON Study Outlook and Robust Commercial Prospects of Zanidatamab
Stifel Nicolaus Keeps Their Buy Rating on Zymeworks (ZYME)
Zymeworks Analyst Ratings
Hold Rating on Zymeworks Amidst Pipeline Adjustments and Clinical Validation Awaited
Hold Rating on Zymeworks Amid Anticipation of Future Clinical Trial Outcomes
Analysts' Opinions Are Mixed on These Healthcare Stocks: Avadel Pharmaceuticals (AVDL), Zymeworks (ZYME) and Aclaris Therapeutics (ACRS)
Hold Rating for Zymeworks Amid New Preclinical Candidate, Regained Rights, and Anticipated Pipeline Progress: A Comprehensive Financial Analysis
Zymeworks Analyst Ratings
H.C. Wainwright Sticks to Its Hold Rating for Zymeworks (ZYME)
Zymeworks (ZYME) Receives a Buy From Stifel Nicolaus
Zymeworks (ZYME) Receives a Hold From H.C. Wainwright